No abstract

In this study, we aimed to evaluate association of ARID1A (AT-rich interacting domain-containing protein 1A) mutation and protein expression with clinicopathology and prognosis of renal cell carcinoma (RCC). Genomic Data Commons (GDC) showed ARID1A was one of the top-ten mutated genes found in kidney cancers and its mutations were found along its sequence. Interestingly, patients with ARID1A mutations had significantly lower survival rate (38%; n=68) comparing to the non-mutated cases (58%; n=192). The results from OSkirc web tool revealed that patients with low expression of ARID1A had significantly shorter overall survival and disease specific survival than those with high ARID1A expression. Immunohistochemistry revealed markedly decreased ARID1A expression in the RCC tissues (n=26), particularly in clear cell RCC (ccRCC) and chromophobe RCC (chRCC). Negative to weak ARID1A expression was significantly associated with ccRCC (grade II) and chRCC subtypes, presence of comorbidity, and low eGFR levels. Finally, ARID1A protein was undetectable in 3/11 cases with ccRCC (grade II) and 2/6 chRCC cases, all of which had metastasis 1−50 months after surgical removal. In conclusion, decreased ARID1A expression is associated with the poor prognosis and metastasis of RCC and thus may serve as the prognostic marker of RCC, particularly ccRCC and chRCC subtypes.